Discounted Cash Flow Rating

Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Summit Therapeutics Inc. Common Stock (SMMT)

Pharmaceutical Preparations

https://www.smmttx.com

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

2882 SAND HILL ROAD, SUITE 106
MENLO PARK, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

03/05/2015

Market Cap

8,510,762,362

Shares Outstanding

700,840,000

Weighted SO

700,842,898

Total Employees

N/A

Upcoming Earnings

08/14/2024

Similar Tickers

NKTX --.--%

CGEM --.--%

KZR --.--%

KRON --.--%

ZVSA --.--%

OCEA --.--%

ZURA --.--%

ELEV --.--%

ICVX --.--%

Beta

-0.9760

Last Div

0.0000

Range

1.52-11.9

Chg

-0.1200

Avg Vol

4128511

Mkt Cap

8510762362

Exch

NASDAQ

Country

US

Phone

617 514 7149

DCF Diff

11.9420

DCF

-0.0720

Div Yield

0.0000

P/S

-36216.0101

EV Multiple

-71.4821

P/FV

42.6394

Div Yield %

0.0000

P/E

-51.4424

PEG

0.3205

Payout

0.0000

Current Ratio

2.3457

Quick Ratio

2.3457

Cash Ratio

0.2051

DSO

-1480.1915

DIO

0.0000

Op Cycle

-1480.1915

DPO

974.5004

CCC

-2454.6919

Gross Margin

6.3234

Op Margin

523.8426

Pretax Margin

688.7319

Net Margin

688.0553

Eff Tax Rate

-0.0319

ROA

-0.4730

ROE

-1.5534

ROCE

-0.6104

NI/EBT

0.9990

EBT/EBIT

1.3148

EBIT/Rev

523.8426

Debt Ratio

0.3180

D/E

0.5572

LT Debt/Cap

0.0251

Total Debt/Cap

0.3578

Int Coverage

-14.0850

CF/Debt

-0.8954

Equity Multi

1.7524

Rec Turnover

-0.2466

Pay Turnover

0.3746

Inv Turnover

0.0000

FA Turnover

-0.0263

Asset Turnover

-0.0007

OCF/Share

-0.1375

FCF/Share

-0.1377

Cash/Share

0.4602

OCF/Sales

414.2121

FCF/OCF

1.0013

CF Coverage

-0.8954

ST Coverage

-0.9388

CapEx Coverage

-798.9284

Div&CapEx Cov

-798.9284

P/BV

42.6394

P/B

42.6394

P/S

-36216.0101

P/E

-51.4424

P/FCF

-87.3242

P/OCF

-85.4520

P/CF

-85.4520

PEG

0.3205

P/S

-36216.0101

EV Multiple

-71.4821

P/FV

42.6394

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 06, 21:58 Summit Therapeutics Inc. Company Investigated by the Portnoy Law Firm GlobeNewswire Inc. Jun 06, 20:50 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brown-Forman Corporation - BF-B; BF-A The Motley Fool May 09, 21:17 Why Recursion Pharmaceuticals Stock Plummeted 24% This Week The Motley Fool Apr 25, 21:05 Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today The Motley Fool Dec 07, 00:09 Why Summit Therapeutics Stock Rocketed 6% Higher on Friday The Motley Fool Oct 27, 18:29 Is Summit Therapeutics a Millionaire Maker? The Motley Fool Oct 13, 16:11 Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics The Motley Fool Oct 12, 13:15 3 Things You Need to Know If You Buy Summit Therapeutics Stock Today The Motley Fool Oct 05, 15:12 Is Summit Therapeutics a Millionaire Maker?

Revenue Product Segmentation